Any new or unusual symptom after dosing. Because this compound has little or no human safety data, there is no established list of 'expected' effects to reassure you against — treat anything abnormal as a signal.
Stop at the first clearly abnormal reaction and reassess. Keep the vial and lot number in case you need to describe what you actually took.
Any severe or fast-worsening symptom — difficulty breathing, chest pain, fainting, severe pain — is a 911 call regardless of the compound.
Allergic reaction: hives, swelling of the lips, tongue or throat, wheezing or dizziness can escalate to anaphylaxis within minutes — call 911 immediately. Site infection: spreading redness, heat, swelling, pus or fever is not wait-and-see; an abscess or cellulitis can need drainage or IV antibiotics. Unverified product: grey-market vials are frequently mislabelled or contaminated, so a reaction may be to endotoxin or the wrong contents, not the named compound.
A heptapeptide analog of ACTH(4-10) extended with a Pro-Gly-Pro tail that confers protease resistance. It lacks the corticotropic activity of the parent hormone. Reported effects centre on increased BDNF and NGF expression in the hippocampus and modulation of monoaminergic systems — the basis for nootropic and neuroprotective claims.
Developed and clinically studied in Russia, where it is a registered medicine for stroke and cognitive indications. The trial literature is largely Russian-language and has not been subjected to Western regulatory review; methodological quality is difficult to assess from outside. Independent replication is limited.
Not FDA-approved. Registered as a medicine in Russia. Not lawfully marketed for human use in the US.
Russian clinical use suggests reasonable tolerability, but this rests on a literature that has not been independently audited. Long-term data unavailable.
A registered medicine in Russia, given intranasally per its national registration. The trial literature is largely Russian-language and not independently validated; not reviewed by the FDA.
Reported from clinical trials or FDA labelling as a matter of record. It is not a recommendation, and for unapproved compounds no dose has been shown safe or effective in humans.
Above is what was administered in trials or on FDA labels, reported as fact. We do not convert it into a personal protocol, calculate a dose for your body weight, or tell you what to inject or how to reconstitute it — that decision belongs with a licensed physician. See our editorial policy.
Regulatory status changes. This page reflects our reading of public sources as of July 2026 and should be independently verified before it is relied upon.